Additive Effect of Oral Insulin and an Oral GLP-1 Agonist on Postprandial Glucose Excursions in a Porcine Model

Miriam Kidron1, Yael Greenberg-Shushlav1, Roy Eldor2 and Ehud Arbit1

1Oramed Pharmaceuticals Ltd., Hi-Tech Park, Givat Ram, Jerusalem, Israel
2Preclinical Services, Menora St., Kfar Ha’oranim, Israel

Received: August 08, 2017; Accepted: August 20, 2017; Published: August 25, 2017;

Abstract

Combination therapy of insulin and a GLP-1 agonist injections is an attractive therapeutic approach in patients with type 2 diabetes mellitus, offering robust glycemic control, a reduced risk of hypoglycemia and weight gain and complementary mechanisms of action. Available combinations of basal insulin preparations and GLP-1 agonists have been shown to be effective and well tolerated in clinical trials. An oral alternative for such combination therapy may improve patient comfort and adherence while potentially offering the added value of liver directed insulin. The aim of this study was to investigate the concomitant pre-prandial delivery of enteric-coated oral insulin (ORMD-0801) and oral exenatide (ORMD-0901) capsules in pigs. The capsules were delivered directly to the duodenum under endoscopic guidance and blood glucose concentrations were monitored over the ensuing three hours. Preprandial delivery of ORMD-0901 or ORMD-0801 fully prevented a post-meal glycemic excursion (p=0.002 and p=0.086 respectively). When given together, a sharp decline >50% of mean baseline values in glycemia was observed, suggesting an additive effect. Peak glycemia was 5.2-fold lower than mean peak values measured in control animals at ~75 min after feeding (p<0.0001). We conclude that co-administration of oral insulin and oral exenatide compared with its components was more effective in controlling postprandial glycemia. The robust additive effect suggests a potential for complementary and non-attenuating mechanisms of action of this oral combination.

Key words: oral insulin, oral exenatide, ORMD-0801, ORMD-0901, combination therapy, T2DM

Introduction

Type 2 diabetes is characterized by a relative insulin deficiency in combination with hyperglycemia, insulin resistance and often obesity [1-3]. A common therapeutic approach to address these metabolic defects combines basal insulin analogs with glucagon-like peptide-1 (GLP-1), concomitantly providing an insulin replacement with the added and complementary benefit of incretin-mediated increases in post-prandial insulin, inhibition of glucagon secretion and weight loss. [2, 4-6]. Several such combinations are currently in different stages of clinical development, including the combination of insulin degludec and the GLP-1 agonist liraglutide (marketed under the brand name Xultophy), [7-9] and the GLP-1 agonist lixisenatide combined with insulin glargine (LixiLan) [10].

Both GLP-1 analogs and insulin are protein-based drugs, currently marketed as injectable preparations only. An oral preparation, whereby the drug is absorbed through the gastrointestinal tract (GIT) and directly into the portal-hepatic venous system, may be better received by patients and perhaps offer a more physiologic mechanism of action, mimicking the hepatic first-pass effect of endogenously secreted insulin and reducing the relative hyperinsulinemia associated with subcutaneous injections. We have previously reported on a specially designed base formulation of this nature that has been shown to enhance GIT absorption of the active proteins and protect them from hydrolysis in the gut [11]. The basis of the enabling technology lies in protein encapsulation, which protects the proteins during transit through the harsh acidic gastric environment and enables them to reach the small intestines, where the capsule is disintegrated in a pH-dependent manner. The plant-derived protease inhibitors (PIs) incorporated into the formulation, provide for further protection from pancreatic and brush border proteases in the small intestines. The approach mimics that observed in neonates, where PIs are naturally incorporated in the maternal colostrum to facilitate transport of critical macromolecules, such as immunoglobulins, growth factors and antigens across the intestinal epithelial barrier [12]. We present here the results of a pre-clinical factorial study examining the post-prandial pharmacodynamic effect in pigs of co-administration of oral human insulin (ORMD-0801) and oral Exenatide, a short-acting GLP-1 agonist (ORMD-0901), as compared to no treatment and the individual agents alone.

Methods and Materials

This study was approved by the Israeli Council of Animal Experimentation, Ministry of Health. Three fasting female, commercial pigs (Ibelin Farm, Israel; age: 3-4 months-old; weight 25-30 kg) were treated in up to eight sessions each, with a minimum two-day washout period between treatments. Animals were housed individually in concrete pens, in a temperature-controlled room (18–24 °C), on a 12:12 light-dark cycle (light hours [07:00 – 19:00]), with olfactory contact between animals. The pigs had free access...
to water by low pressure drinking nipples. Fasting animals were anesthetized with isoflurane (2L O₂ per minute and 5% isoflurane), intubated and mechanically ventilated. Pigs were positioned on their left side while enteric-coated capsules were administered directly to the duodenum under endoscopic guidance. On test days when both ORM-D-0801 and ORM-D-0901 were administered, ORM-D-0901 (150 mg) was delivered first, followed by the ORM-D-0801 (8 mg) capsule within 2-10 minutes. The pigs were fed Denkavit powdered milk for pigs (10 g/kg body weight) 30 min after drug administration and after recovering from anesthesia (10-15 minutes). Blood glucose was monitored via blood samples periodically drawn from a central line catheter over the 240-min post-dosing period. Piglets were intravenously treated with gentamycin (100 mg/10 kg) from a central line catheter over the 240-min post-dosing period. Upon completion of the set of experiments, animals were euthanized with intravenously administered pentobarbital 1ml/1.5kg body weight.

**Results**

When preprandially treated with ORM-D-0901 alone or ORM-D-0801 alone, blood glucose excursions were significantly curbed, as compared to untreated meals (Figure 1). When ORM-D-0901 and ORM-D-0801 were administered together, a robust drop in blood glucose which was significantly greater than following treatment with each drug alone, was observed (Figure 1; p-value < 0.001). Blood glucose concentrations dropped to hypoglycemic levels (~20mg/dL) which were 5.2-fold lower than mean peak values measured in control meals at ~75 min after feeding (p<0.0001) and remained at a low of >50% below baseline values until the end of the 180-minute monitoring session.

Fasting, commercial pigs were treated with ORM-D-0901 (150 mg exenatide; squares), ORM-D-0801 (8 mg insulin; triangles) or both ORM-D-0901 and ORM-D-0801 (circles) capsules, 30 minutes before caloric intake. Blood samples (1 mL) were periodically drawn throughout the 180-minute observation period to determine glucose concentrations.

**Discussion**

This pre-clinical factorial study assessed the feasibility of simultaneous oral delivery of two hormones with complimentary modes of action [13]. Oral co-administration of human insulin and exenatide, provided a robust antihyperglycemic effect, curbing postprandial glucose excursions. The extent of the combined effect suggests an additive effect, resulting in a glycemic drop to a significantly hypoglycemic range. In the proposed combination regimen, insulin deficiency is supplemented by exogenous insulin administration, which is expected to increase glucose utilization and retard hepatic glucose production through direct actions in muscle, adipose tissue and the liver. At the same time, the GLP-1 analog was integrated to stimulate endogenous glucose-responsive insulin secretion, inhibit glucagon secretion and slow gastric emptying [2]. In addition, the GLP-1 component has been reported to induce satiety, lead to decreased food intake and eventually reduce body weight [14]. Moreover, owing to the glucose-dependent insulinitrophic effect of GLP-1 and because glucagon-like peptide-1 receptor agonists (GLP-1RAs) preserve or even augment the glucagon response to hypoglycemia [2,15] the GLP-1RA-insulin combination is likely to allow for a reduction in insulin doses.

The importance of the hepatoportal system and liver, as they relate to insulin, is well known, [16] but existence of a hepato-preferential effect of incretin hormones is less clear at this time. As with insulin, there is a hepato-systemic GLP-1 gradient in the portal circulation, with several fold higher GLP-1 concentrations than in the systemic circulation [17]. Accumulating data suggest a role for GLP-1 in the liver and portal system in glucose and fat metabolism, as well as in satiety [18]. Among its known hepatic effects, GLP-1 stimulates glycogen synthesis in isolated rat hepatocytes, [19] and suppresses hepatic glucose production independently of plasma insulin, glucagon and glucose levels [20]. In both animal models [21] and humans [22] treatment with exendin-4 or liraglutide decreased hepatic lipid content and inflammation and decreased hepatic steatosis. While the GLP-1R is expressed on hepatic portal vagal afferents, suggesting indirect mediation of GLP-1 effects by central nervous system (CNS) activity, evidence regarding the presence of GLP-1R on hepatocytes remains conflicting.

Several injectable combinations of long-acting basal insulin and long- or short-acting GLP-1 analogs are in different stages of clinical development. This study is unique in that we show a robust antihyperglycemic effect of the combination of both an oral short-acting insulin and an oral short-acting GLP-1 agonist. The oral absorption of insulin and GLP-1 analog is enabled by Oramed's core technology and formulation. This proprietary technology is comprised of a combination of encapsulation to shield the polypeptide (GLP-1) during transit in the gastrointestinal tract and protease inhibitors
that reduce its proteolytic degradation. The protease inhibitors are plant derived and comprised of α-chymotrypsin inhibitors. The encapsulation consist of a polymer with pH-dependent solubility that relies on pH gradients in the intestine for site-specific dissolution [23]. Taken together, the encouraging results presented here, along with the projected long-term clinical benefits of the combined therapy, warrant clinical studies with such short – prandial combinations in patients with diabetes.

The limitations of the study include the absence of a true placebo/sham endoscopic procedure, the lack of pharmacokinetic (PK) analyses for both exenatide and insulin and the small number of animals examined. Given that the study was a preliminary study, it was deemed acceptable to withhold administration of a placebo before the meal challenge. As for insulin PK, the clear hypoglycemic effect suggests a significant increase in peripheral insulin. Whether this is the result of the administered oral insulin or endogenously secreted insulin in response to the effect of exenatide in the context of a meal and absorbed glucose remains to be determined. Since up to 80% of secreted insulin is sequestered within the liver upon first-pass metabolism, resulting in minimal doses in the peripheral circulation [24, 25] estimation of insulin bioavailability and PK analyses would not have provided useful information, unless there is direct sampling from the portal vein.

Furthermore, under physiologic circumstances, endogenous secretion of insulin is a dynamic process, whereby the levels of secreted insulin change from moment to moment depending on ambient glucose levels [26]. As for exenatide PK analyses, non-proprietary analytical methods for the quantitation of exenatide, such as immunoadsorb (ELISA) and high-performance liquid chromatographic–tandem mass spectrometry (HPLC/MS/MS) method are plagued by low precision, poor repeatability and specificity and also potential interferences by endogenous compounds [27]. Only recently has a commercial and validated enzyme-linked immunoabsorbent assay kit (Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA) become available for procurement. Nonetheless, the pharmacodynamic observations of the additive effect of the combination treatment compared to no treatment or to treatment with insulin or exenatide alone are compelling and it is unlikely that this significant effect could be attained short of the combined effect of insulin and exenatide.

**Authorship**

MK: Conception and design of study, drafting and revising manuscript. YGS, RE and EA are consultants at Oramed. MK is the CTO and hold shares at Oramed Pharmaceuticals.

**References**


**Abbreviations**

CNS: central nervous system
ELISA: enzyme-linked immunoabsorbent assay

**Competing Interests**

MK is the CTO and hold shares at Oramed Pharmaceuticals.

**Endocrinol Diabetes Metab J, Volume 1(3): 3–4, 2017**


Citation:

*Endocrinol Diabetes Metab J*, Volume 1(3): 4–4, 2017